A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer

Robertson, John F. R.; Jiang, Zefei; Di Leo, Angelo; Ohno, Shinji; Pritchard, Kathleen I.; Ellis, Matthew; Bradbury, Ian; Campbell, Christine

doi:10.1007/s12282-019-00973-4

Research Repository

All Outputs (2)

A Hybrid Evolutionary Strategy to Optimise Early-Stage Cancer Screening (2019)
Conference Proceeding

Current methods to identify cutoff values for tumour-associated molecules (antigens) discrimination are based on statistics and brute force. These methods applied to cancer screening problems are very inefficient, especially with large data sets with... Read More about A Hybrid Evolutionary Strategy to Optimise Early-Stage Cancer Screening.

A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer (2019)
Journal Article

Background Fulvestrant, a selective estrogen receptor degrader, is approved for first- and second-line treatment of postmenopausal women with hormone receptor-positive advanced breast cancer (ABC). Methods Meta-analysis of randomized controlled... Read More about A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer.